International Variation in Treatment Procedures for ADHD: Social Context and Recent Trends
Supplemental Material
Hinshaw DS.pdf (42 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×Hinshaw DS.pdf (42 KB)
Work on this article was partly supported by an Investigator Award in Policy Research from the Robert Wood Johnson Foundation. Additional funds were provided by the Center for Child and Youth Policy, the Nicholas C. Petris Center, and the Department of Psychology, all of the University of California, Berkeley. The authors gratefully acknowledge Brad Berman, M.D., Glen Elliott, M.D., Ph.D., Howard Goldman, M.D., Ph.D., Peter Jensen, M.D., and Tony Philipps, M.D., who moderated sessions and facilitated discussion at the workshop described in this article. Stephen Robitaille, B.A., provided valuable assistance preparing the survey. Amy Nuttbrock, B.A., facilitated all aspects of the workshop. Candy Pareja, B.A., provided editorial assistance and B. Tate Guelzow, M.A., Fred Loya, M.A, Liat Tikotzky, Ph.D., and Chandrakala Ganesh, Ph.D., provided assistance in note taking.
Dr. Banaschewski has served in an advisory or consultancy role for Desitin, Eli Lilly and Company, Medice, Novartis, Pfizer, Shire, UCB, and Viforpharma; has received conference attendance support or speaker's fees from Lilly, Janssen McNeil, Medice, Novartis, Shire, and UCB; and has been involved in clinical trials conducted by Lilly, Shire, and Novartis. Dr. Mattos is on the advisory board of Novartis, Janssen-Cilag, and Shire and has received research funds from Shire and Novartis. Dr. Sergeant is on the advisory boards of Lilly, Novartis, and Shire; has a research grant from Lilly; and has received speaker's fees from Shire, Lilly, and Janssen-Cilag. Dr. Weiss has received research funds from and has had consultation and speaker arrangements with Purdue, Shire, Lilly, and Janssen. The other authors report no competing interests.